Form 8-K

8-K — Co-Diagnostics, Inc.

Accession: 0001493152-26-034837

Filed: 2026-07-27

Period: 2026-07-27

CIK: 0001692415

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Entry into a Material Definitive Agreement

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-5.1 (ex5-1.htm)

EX-10.1 (ex10-1.htm)

GRAPHIC (ex5-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001692415

2026-07-27

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of The

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): July 27, 2026

CO-DIAGNOSTICS,

INC.

(Exact

name of registrant as specified in its charter)

Utah

001-38148

46-2609363

(State

or other jurisdiction

incorporation)

(Commission

File Number)

(IRS

Employer

Identification

No. )

2401

S. Foothill Drive, Suite D, Salt Lake City Utah 84109

(Address

of principal executive offices) (Zip Code)

(801)

438-1036

Registrant’s

telephone number, including area code

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $0.001 per share

CODX

The

Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

1.01. Entry into a Material Definitive Agreement

previously disclosed, on October 20, 2025, Co-Diagnostics, Inc., a Utah corporation (the “Company”), entered into an equity

distribution agreement (the “Original Equity Distribution Agreement”) with Maxim Group LLC (“Maxim”).

July 27, 2026, the Company and Maxim entered into an amendment to the Original Equity Distribution Agreement (the “Equity Distribution

Agreement Amendment”), which, among other things, removed the fixed aggregate dollar limitation on sales under the Original Equity

Distribution Agreement, such that future offers and sales of our Common Stock will be limited solely by the amount of Common Stock currently

registered and available for issuance under our effective registration statement.

The

offer and sale of the shares is being made pursuant to the Shelf Registration Statement (Registration No. 333-295803) and the related

prospectus supplement dated July 27, 2026 (the “Prospectus Supplement”) filed by the Company with the Securities and Exchange

Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended.

The

foregoing description of the Equity Distribution Agreement Amendment is only a summary and is qualified in its entirety by reference

to the full text of the Equity Distribution Agreement Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and

incorporated herein by reference.

In connection with the Company’s entry

into the Equity Distribution Agreement Amendment and filing of the Prospectus Supplement, the Company also agreed with the investors

under the Securities Purchase Agreement dated May 19, 2026, to extend the period during which the Company will not issue, enter into

any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or any securities convertible into

or exercisable or exchangeable for shares of Common Stock or file any registration statement or prospectus, or any amendment or supplement

thereto to 5:00 pm Eastern Time on August 14, 2026.

The

legal opinion of Dorsey & Whitney LLP relating to the shares being offered pursuant to the Equity Distribution Agreement (as amended

by the Equity Distribution Agreement Amendment) and the Prospectus Supplement is filed as Exhibit 5.1 to this Current Report on Form

8-K.

This

Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the shares as discussed

herein, nor shall there be any sale of the shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful

prior to registration or qualification under the securities laws of any such state or jurisdiction.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

5.1

Opinion of Dorsey & Whitney LLP

10.1

Amendment to Equity Distribution Agreement, by and between Co-Diagnostics, Inc. and Maxim Group LLC, dated July 27, 2026.

23.1

Consent of Dorsey & Whitney LLP (included in Exhibit 5.1).

104

Cover

Page Interactive Data File (embedded within the inline XBRL Document)

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned, hereunto duly authorized.

CO-DIAGNOSTICS,

INC.

Date:

July 27, 2026

By:

/s/

Brian Brown

Name:

Brian

Brown

Title:

Chief

Financial Officer

(Principal

Financial and Accounting Officer)

EX-5.1

Filename: ex5-1.htm · Sequence: 2

Exhibit 5.1

July

27, 2026

Co-Diagnostics,

Inc.

2401

S. Foothill Drive, Suite D

Salt

Lake City, Utah 84109

Re:

Registration

Statement on Form S-3 (File No. 333-295803)

have acted as counsel to Co-Diagnostics, Inc., a Utah corporation (the “Company”), in connection with the filing by the Company

with the Securities and Exchange Commission (the “Commission”) of a Prospectus Supplement (the “Prospectus Supplement”),

dated July 27, 2026, to the Prospectus, dated May 15, 2026, included in the Registration Statement on Form S-3 (File No. 333-295803)

filed by the Company with the Commission under the Securities Act of 1933, as amended (the “Securities Act”), relating to

the offer and sale by the Company of up to $7,901,383 of shares of the Company’s common stock, par value $0.001 per share

(the “Shares”), pursuant to that certain Equity Distribution Agreement, dated October 20, 2025 and amended on July 27,

2026 (the “Offering Agreement”), between the Company and Maxim Group LLC.

have examined such documents and have reviewed such questions of law as we have considered necessary or appropriate for the purposes

of our opinions set forth below. In rendering our opinions set forth below, we have assumed the authenticity of all documents submitted

to us as originals, the genuineness of all signatures and the conformity to authentic originals of all documents submitted to us as copies.

We have also assumed the legal capacity for all purposes relevant hereto of all natural persons. As to questions of fact material to

our opinions, we have relied upon certificates or comparable documents of officers and other representatives of the Company and of public

officials.

Based

on the foregoing, we are of the opinion that:

The

Shares, when issued and delivered against payment of the consideration therefor specified in the Offering Agreement, will be validly

issued, fully paid, and non-assessable.

Our

opinions expressed above are limited to the laws of the State of Utah.

hereby consent to the filing of this opinion as an exhibit to a Current Report on Form 8-K to be filed by the Company with the Commission,

which Current Report on Form 8-K will be incorporated by reference into the Registration Statement, and to the reference to our firm

under the heading “Legal Matters” in the Prospectus Supplement. In giving this consent, we do not admit that we are within

the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission

thereunder.

Very truly

yours,

/s/ Dorsey & Whitney

LLP

DPL/JBE

EX-10.1

Filename: ex10-1.htm · Sequence: 3

Exhibit

10.1

FIRST

AMENDMENT TO

EQUITY

DISTRIBUTION agreement

This

FIRST AMENDMENT TO EQUITY DISTRIBUTION AGREEMENT (this “Amendment”) is entered into as of July 27, 2026, by

and between Co-Diagnostics, Inc., a Utah corporation (the “Company”), and Maxim Group LLC (the “Agent”).

WHEREAS,

the Company and the Agent entered into an Equity Distribution Agreement, dated October 20, 2025 (the “Agreement”),

pursuant to which the Company may issue and sell, through the Agent, its shares of common stock;

WHEREAS,

the Agreement provides that the Company may cause the Agent to sell common stock of the Company having an aggregate offering price of

up to $10 million;

WHEREAS,

the Company and the Agent wish to amend the introductory paragraph and Sections 2(a) and 7(a) of the Agreement to remove the limit on

the number of shares of the Company’s common stock that may be sold pursuant to the Agreement;

WHEREAS,

sales of the Common Stock under the Agreement have been made pursuant to the Company’s registration statement on Form S-3 (File

No. 333-270628), initially declared effective by the Securities and Exchange Commission (the “Commission”) on April

6, 2023 (as amended or supplemented from time to time, the “Existing Registration Statement”);

WHEREAS,

the Company filed a new base registration statement on Form S-3 (File No. 333-295803) with the Commission, which was declared effective

on May 15, 2026, and intends to file a prospectus supplement to such registration statement to register additional shares of Common Stock

for offer and sale under the Agreement (the registration state together with such prospectus supplement, the “New Registration

Statement”); and

WHEREAS,

the parties desire to amend the Agreement to provide that, all references in the Agreement to the registration statement and related

documents shall be deemed to include the New Registration Statement and the corresponding documents relating thereto.

NOW,

THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable consideration, the receipt and sufficiency

of which are hereby acknowledged, and intending to be legally bound hereby, the Company and the Agent hereby agree as follows:

Amendment to the Introductory Paragraph of the Agreement. The introductory paragraph of the Agreement is hereby amended and restated

in its entirety as follows:

“Co-Diagnostics,

Inc., a Utah corporation (the “Company”), proposes to issue and sell through Maxim Group LLC (the “Agent”),

as sales agent, shares of common stock, par value $0.001 per share (“Common Stock”), of the Company (the “Shares”)

on terms set forth herein. The Shares consist entirely of authorized but unissued shares of Common Stock to be issued and sold by the

Company.”

Amendment to “Purchase, Sale and Delivery of Shares.” Sections 2(a) and 2(a)(i) of the Agreement is hereby

amended and restated in its entirety as follows:

(a)

At the Market Sales. On the basis of the representations, warranties and agreements herein the Company agrees that, from time

to time on the terms and subject to the conditions set forth herein, it may issue and sell through the Agent, acting as sales agent,

Shares; provided, however, that in no event shall the Company issue or sell through the Agent such number of Shares that (a) exceeds

the number or dollar amount of shares of Common Stock registered on the Registration Statement pursuant to which the Offering is being

made, (b) exceeds the number of authorized but unissued shares of Common Stock under the Company’s Articles of Incorporation, as

amended or (c) would cause the Company or the Offering to not satisfy the eligibility and transaction requirements for use of Form S-3

(including, if then applicable, General Instruction I.B.6 of Form S-3) (the lesser of (a), (b) and (c), the “Maximum Amount”).

Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitations set forth in

this Section 2(a) on the number and aggregate sales price of Shares issued and sold under this Agreement shall be the sole responsibility

of the Company and the Agent shall have no obligation in connection with such compliance. Notwithstanding the foregoing, the Company

agrees that it will provide the Agent with written notice of the Maximum Amount available for sale of the Shares no less than one (1)

Business Day prior to the date on which it makes the initial sale of Shares under this Agreement. “Business Day”,

as used herein, shall mean any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized

or required by law to remain closed; provided that banks shall not be deemed to be authorized or obligated to be closed due to a “shelter

in place,” “non-essential employee” or similar closure of physical branch locations at the direction of any governmental

authority if such banks’ electronic funds transfer systems (including for wire transfers) are open for use by customers on such

day.

(i)

For purposes of selling the Shares through the Agent, the Company hereby appoints the Agent as exclusive agent of the Company for the

purpose of soliciting purchases of the Shares from the Company pursuant to this Agreement and the Agent agrees to use its commercially

reasonable efforts to sell the Shares on the terms and subject to the conditions stated herein.

3. Amendment

to “Termination of this Agreement.” Section 7 of the Agreement is

hereby amended and restated in its entirety as follows:

“7. Termination

of this Agreement. The term of this Agreement shall begin on the date hereof, and shall continue until termination by either the Agent

and the Company upon the provision of ten (10) days written notice. Any such termination by mutual agreement shall in all cases be deemed

to provide that Section 3(g), Section 5 and Section 6 shall remain in full force and effect. Notwithstanding the foregoing, the Agent

shall have the right, in its sole discretion, to terminate this Agreement if at any time from the date of this Agreement to the effectiveness

of the Registration Statement, the Agent is not fully satisfied, in its sole discretion, with the results of its and its representatives’

review of the Company and the Company’s business.”

New Registration Statement.

a. As

used in this Amendment and the Agreement, the term “New Registration Statement”

shall mean any new registration statement on Form S-3 (or any successor form thereto) filed

by the Company with the Commission after October 20, 2025 for purposes of registering the

offer and sale of shares of Common Stock under the Agreement, including all amendments thereto,

all documents filed as a part thereof or incorporated by reference therein, and any registration

statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the

“Securities Act”), to register additional shares of Common Stock.

b. Upon

the effectiveness of any New Registration Statement, all references in the Agreement to “Registration

Statement,” “Base Prospectus,” “Prospectus,” “Prospectus

Supplement,” and any other defined terms relating to the registration statement and

the prospectus included therein shall be deemed to refer to, and include, as applicable,

the corresponding documents forming part of or relating to such New Registration Statement,

the base prospectus included therein and any prospectus supplement thereto. All representations,

warranties, covenants, agreements, and conditions set forth in the Agreement with respect

to the Existing Registration Statement and the prospectus included therein shall apply to

each New Registration Statement and the prospectus included therein with the same force and

effect as if originally made with respect thereto.

No Further Amendment. Except as amended by this Amendment, the Agreement remains unaltered and shall remain in full force and

effect.

Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Amendment shall be determined

in accordance with the provisions of the Agreement.

Counterparts. This Amendment may be executed in any number of counterparts, each of which will be deemed an original and all of

which together will constitute one and the same instrument. Signatures delivered by facsimile, electronic mail (including as a PDF file)

or other transmission method shall be deemed to be original signatures, shall be valid and binding, and, upon delivery, shall constitute

due execution of this Amendment.

[Signature

page follows]

WITNESS WHEREOF, each of the Company and the Agent has caused this Amendment to be executed and delivered by its officer thereunto duly

authorized as of the date first above indicated.

COMPANY

CO-DIAGNOSTICS, INC.

By:

/s/ Dwight H. Egan

Name:

Dwight H. Egan

Title:

Chief Executive Officer

AGENT

MAXIM GROUP LLC

By:

/s/ Ritesh Veera

Name:

Ritesh Veera

Title:

Co-Head of Investment Banking

GRAPHIC

Filename: ex5-1_001.jpg · Sequence: 4

Binary file (10125 bytes)

Download ex5-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Jul. 27, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 27, 2026

Entity File Number

001-38148

Entity Registrant Name

CO-DIAGNOSTICS,

INC.

Entity Central Index Key

0001692415

Entity Tax Identification Number

46-2609363

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2401

S. Foothill Drive

Entity Address, Address Line Two

Suite D

Entity Address, City or Town

Salt Lake City

Entity Address, State or Province

Entity Address, Postal Zip Code

84109

City Area Code

(801)

Local Phone Number

438-1036

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.001 per share

Trading Symbol

CODX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration